The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience.
Since January 2000 we have administered entacapone (200 mg) to 75 patients with severe Parkinson's disease in combination with their routine levodopa dose. At baseline the mean UPDRS (item III) score was 38+/-6. After 3 months of entacapone therapy the patients presented a significant improvement of motor fluctuations; the mean UPDRS score (item III) was 20+/-4. This improvement was also statistically significant after 2 years of entacapone therapy.
Paci
C
C
Department of Neurology, Madonna del Soccorso Hospital, San Benedetto del Tronto (AN), Italy.
Sanguigni
S
S
Carboni
T
T
Gobbato
R
R
Curatola
L
L
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002396:Catechols / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D009043:Motor Activity / Q000187:drug effects; D009460:Neurologic Examination; D009570:Nitriles; D010300:Parkinson Disease / Q000188:drug therapy*; D011446:Prospective Studies; D013997:Time Factors
D000978:Antiparkinson Agents; D002396:Catechols; D009570:Nitriles; D007980:Levodopa; C071192:entacapone